精神药物使用与社区老年人步态及活动能力受损的关联:TILDA研究
基于爱尔兰老龄化纵向研究(TILDA)队列,纳入2620名≥60岁社区老年人,分析精神药物(抗抑郁药、苯二氮䓬类、Z类药物、抗精神病药、抗胆碱能药)与步态及活动能力的关系。结果显示,12%使用≥1种精神药物,横断面和纵向均与步态及活动能力变差独立相关,提示应将精神药物审查纳入老年综合评估。
要点
- 使用精神药物与步速减慢、步长缩短、双重支撑期延长及计时起立行走延长独立相关
- 纵向使用精神药物与转为异常计时起立行走风险升高相关(OR 2.68)
- 使用≥2种精神药物与转为步速减慢风险升高相关(OR 2.59)
核心结论
- 精神药物使用与社区老年人活动能力和步态表现显著变差相关,横断面和纵向均成立。
- 应将精神药物使用审查作为老年综合评估的一部分。
研究设计与样本
- 基于TILDA Wave 1的队列研究,纳入≥60岁且完成步态与活动能力评估(Gaitrite系统)的社区老年人,Wave 3(4年后)随访。
- 共纳入2620名参与者,分析精神药物(抗抑郁药、苯二氮䓬类、Z类药物、抗精神病药、抗胆碱能药)与活动能力/步态参数的关系。
- 采用回归模型评估横断面关联,多水平模型评估纵向轨迹。
主要发现
- 2620名参与者中,12%被处方≥1种精神药物,3%被处方≥2种精神药物。
- 横断面分析中,精神药物使用与计时起立行走延长独立相关(β=0.50,95%CI 0.27-0.73,p<.001)。
- 横断面分析中,精神药物使用与步速减慢独立相关(β=-5.65,95%CI -7.92至-3.38,p<.001)。
- 横断面分析中,精神药物使用与步长缩短独立相关(β=-2.03,95%CI -2.93至-1.42,p<.001),并与双重支撑期增加独立相关(β=0.47,95%CI 0.19-0.75,p=.001)。
- 纵向分析中,精神药物使用与转为异常计时起立行走独立相关(OR 2.68,95%CI 1.55-4.64,p<.001);使用≥2种精神药物与转为步速减慢相关(OR 2.59,95%CI 1.01-6.68,p=.048)。
临床怎么用
- 在老年综合评估中应常规审查精神药物使用,关注其对步态和活动能力的潜在不良影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little work to date has quantified the effect of psychotropic medications (antidepressants, benzodiazepines, "Z" drugs, antipsychotics, anticholinergics) on mobility and gait in later life. The aim of this study is to examine the relationship between these medications and mobility/gait parameters in a large cohort of community-dwelling older people. METHODS: Participants were included if they were aged ≥60 years at TILDA Wave 1 and underwent gait and mobility assessment (Gaitrite system), with follow-up at Wave 3 (4 years). Medication lists were examined for psychotropic medications. Regression models assessed the relationship between psychotropic medications and mobility using the following parameters: Timed Up and Go, gait speed, step length/width, and double support phase. Multilevel modeling assessed trajectories of mobility/gait variables over time by psychotropic use. RESULTS: Of 2620 patients, 12% were prescribed ≥1 psychotropic medication, and 3% prescribed ≥2 psychotropics. Cross-sectionally, psychotropic medication was independently associated with prolonged Timed Up and Go (β = 0.50 [95% confidence interval {CI} 0.27-0.73]; p < .001), slower gait speed (β = -5.65 [95% CI -7.92 to -3.38]; p < .001), shorter step length (β = -2.03 [95% CI -2.93 to -1.42]; p < .001), and increased double support phase (β = 0.47 [95% CI 0.19-0.75]; p = .001). Longitudinally, psychotropic use was independently associated with transition to abnormal Timed Up and Go (odds ratio 2.68 [95% CI 1.55-4.64], p < .001), whereas using ≥2 psychotropics was associated with transition to slower gait speed (odds ratio 2.59 [95% CI 1.01-6.68]; p = .048). CONCLUSIONS: Psychotropic use was associated with significantly poorer mobility and gait performance, both cross-sectionally and longitudinally. It is imperative that psychotropic medication use is reviewed as part of a comprehensive geriatric assessment.
引用
- O' Donnell D, Moriarty F, Lavan A, et al. The Association Between Psychotropic Medication Use and Gait and Mobility Impairment in Community-Dwelling Older People: Data From The Irish Longitudinal Study on Ageing (TILDA). J Gerontol A Biol Sci Med Sci. 2025. PMID: 39501425. doi:10.1093/gerona/glae263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。